Ambeed.cn

首页 / 抑制剂/激动剂 / 膜转运蛋白 / 氯离子通道 / T16Ainh-A01

T16Ainh-A01 {[allProObj[0].p_purity_real_show]}

货号:A648561 同义名: T16A(inh)-A01

T16Ainh-A01是一种氨基苯噻唑类化合物,是强效的转膜蛋白16A(TMEM16A)抑制剂,能抑制TMEM16A介导的氯离子电流,IC50约为1 µM。TMEM16A(ANO1)作为钙激活的氯通道(CaCC)。

T16Ainh-A01 化学结构 CAS号:552309-42-9
T16Ainh-A01 化学结构
CAS号:552309-42-9
T16Ainh-A01 3D分子结构
CAS号:552309-42-9
T16Ainh-A01 化学结构 CAS号:552309-42-9
T16Ainh-A01 3D分子结构 CAS号:552309-42-9
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

T16Ainh-A01 纯度/质量文件 产品仅供科研

货号:A648561 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >

T16Ainh-A01 生物活性

描述 T16Ainh-A01, an aminophenylthiazole, is a potent transmembrane protein 16A (TMEM16A) inhibitor, inhibiting TMEM16A-mediated chloride currents with an IC50 value of ~1 µM. TMEM16A (ANO1) functions as a calcium-activated chloride channel (CaCC). Depolarization-evoked I ClCa in isolated RUICC, recorded using voltage clamp, were inhibited by T16Ainh-A01 with IC50 values of 3.4 μM. Eurogenic contractions of strips of rabbit urethra smooth muscle (RUSM), evoked by electric field stimulation (EFS), were also significantly reduced by T16Ainh-A01[1]. T16Ainh-A01 (10 μM) inhibits nearly completely TMEM16A chloride current (induced by 275 nM free calcium in the pipette) at all voltages, indicating a voltage-independent block mechanism[2]. T16Ainh-A01 led to the significant repression of cell proliferation, cell migration, and collagen secretion in CFs(cardiac fibroblasts)[3]. Suppression of ANO1 activity either by selective inhibitor (T16Ainh-A01) or by siRNA significantly attenuated the migration and invasion of ATC (Anaplastic thyroid carcinoma) cells[4].

T16Ainh-A01 细胞实验

Cell Line
Concentration Treated Time Description References
Mouse retinal rod bipolar cells 10 µM 200 milliseconds Inhibited outward rectifying current, confirming the voltage-dependent component of ANO1 Cells. 2020 Feb 26;9(3):543
SH-SY5Y cells 10–30 µM 24 hours Evaluate the effect of T16Ainh-A01 on HRSV-GFP expression, results showed significant reduction in HRSV-GFP expression Thorax. 2021 Jan;76(1):64-72
A549 cells 5–30 µM 24 hours Evaluate the effect of T16Ainh-A01 on HRSV-GFP expression, results showed significant reduction in HRSV-GFP expression Thorax. 2021 Jan;76(1):64-72
HaCaT keratinocytes 30 µM 3 days Inhibition of HaCaT cell proliferation and reduction of pERK1/2 phosphorylation Int J Mol Sci. 2021 Jul 1;22(13):7145
Vascular smooth muscle cells (VSMCs) 10 µM 30 minutes Inhibiting TMEM16A activity, significantly reducing the expression of VCAM-1 and ICAM-1 Biomedicines. 2022 Oct 31;10(11):2760
Mouse retinal rod bipolar cells 40 µM 300 seconds Inhibited ANO1 tail current (I tail), indicating ANO1 is activated by Ca2+ Cells. 2020 Feb 26;9(3):543
Mouse cardiac vascular endothelial cells (CVECs) 30 µM 48 hours To evaluate the effect of T16Ainh-A01 on CVECs proliferation, results showed T16Ainh-A01 did not affect cell growth Br J Pharmacol. 2014 Aug;171(15):3680-92
Dorsal root ganglia neurons 20 µM and 100 µM 90 seconds ANO1 blockade with T16Ainh-A01 significantly inhibited the PGE2-evoked axonal depolarisation Sci Rep. 2024 Jul 29;14(1):17360

T16Ainh-A01 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6N mice Cerulein-induced acute pancreatitis model Intraperitoneal injection 1 mg/kg Single injection, lasting 12 hours To investigate the effect of T16Ainh-A01 on the acute pancreatitis mouse model, results showed that T16Ainh-A01 ameliorated pancreatic damage and reduced IL-6 levels in serum and pancreatic tissues. J Adv Res. 2020 Jan 21;23:25-35
Genetically epilepsy-prone rats (GEPR-3s) Genetically epilepsy-prone rat model Oral 10 mg/kg Single dose, tested 30 minutes after administration To evaluate the effects of T16Ainh-A01 on acoustically evoked seizures in GEPR-3s. Results showed that T16Ainh-A01 pretreatment did not significantly alter the incidence of WRSs and GTCSs, seizure latency, seizure duration, or seizure severity. Biomedicines. 2022 Feb 15;10(2):449
Sprague-Dawley rats Chronic constriction injury (CCI) model Intrathecal injection 10 μg Once every 6 hours, totally five times To evaluate the effect of T16Ainh-A01 on CCI-induced neuropathic pain. Results showed that T16Ainh-A01 significantly alleviated thermal hyperalgesia, reduced the excitability of DRG neurons, and decreased TMEM16A expression. Neural Regen Res. 2019 Jun;14(6):1091-1098
Guinea pig Tracheal rings Organ baths 10 μM, 50 μM, 100 μM 30-minute intervals To investigate the relaxant effect of T16Ainh-A01 on acetylcholine-induced contraction. Results showed that 50 μM and 100 μM T16Ainh-A01 significantly relaxed the acetylcholine-induced contraction. Anesthesiology. 2015 Sep;123(3):569-81
BALB/c mice IMQ-induced psoriasis-like skin injury model Topical application on ears 30 µM and 100 µM Once daily for 7 consecutive days Alleviation of psoriasis-like symptoms and reduction of ANO1 and pERK1/2 expression Int J Mol Sci. 2021 Jul 1;22(13):7145
Mice Pain-related behavior model Hind paw injection 300 μM Single injection, observed for 5 minutes Investigate the effect of ANO1 antagonist T16Ainh-A01 on capsaicin-induced pain-related behaviors, finding that A01 significantly reduced capsaicin-induced pain behaviors Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5213-8

T16Ainh-A01 参考文献

[1]Fedigan S, Bradley E, Webb T, Large RJ, Hollywood MA, Thornbury KD, McHale NG, Sergeant GP. Effects of new-generation TMEM16A inhibitors on calcium-activated chloride currents in rabbit urethral interstitial cells of Cajal. Pflugers Arch. 2017 Nov;469(11):1443-1455

[2]Namkung W, Phuan PW, Verkman AS. TMEM16A inhibitors reveal TMEM16A as a minor component of calcium-activated chloride channel conductance in airway and intestinal epithelial cells. J Biol Chem. 2011 Jan 21;286(3):2365-74

[3]Tian XQ, Ma KT, Wang XW, Wang Y, Guo ZK, Si JQ. Effects of the Calcium-Activated Chloride Channel Inhibitors T16Ainh-A01 and CaCCinh-A01 on Cardiac Fibroblast Function. Cell Physiol Biochem. 2018;49(2):706-716

[4]Kim JY, Youn HY, Choi J, Baek SK, Kwon SY, Eun BK, Park JY, Oh KH. Anoctamin-1 affects the migration and invasion of anaplastic thyroid carcinoma cells. Anim Cells Syst (Seoul). 2019 May 10;23(4):294-301

T16Ainh-A01 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

12.00mL

2.40mL

1.20mL

24.01mL

4.80mL

2.40mL

T16Ainh-A01 技术信息

CAS号552309-42-9
分子式C19H20N4O3S2
分子量 416.52
SMILES Code O=C(NC1=NC(C2=CC=C(OC)C=C2)=CS1)CSC3=NC(C)=C(CC)C(N3)=O
MDL No. MFCD03278952
别名 T16A(inh)-A01
运输蓝冰
InChI Key QSIYTNYMBWYHAA-UHFFFAOYSA-N
Pubchem ID 135460621
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry,Store in freezer, under -20°C

溶解方案

DMSO: 85 mg/mL(204.07 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

DMF: 10 mg/mL(24.01 mM)

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。